Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBITDA Margin: 2012-2025

Historic EBITDA Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to -907.37%.

  • Agios Pharmaceuticals' EBITDA Margin rose 23956.00% to -907.37% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,061.80%, marking a year-over-year increase of 17630.00%. This contributed to the annual value of -1,166.47% for FY2024, which is 29305.00% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' EBITDA Margin is -907.37%, which was up 11.05% from -1,020.12% recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year EBITDA Margin high stood at -907.37% for Q3 2025, and its period low was -12,156.85% during Q1 2022.
  • Over the past 3 years, Agios Pharmaceuticals' median EBITDA Margin value was -1,221.97% (recorded in 2025), while the average stood at -1,244.15%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 1,054,136bps in 2023, then tumbled by 9,763bps in 2025.
  • Quarterly analysis of 4 years shows Agios Pharmaceuticals' EBITDA Margin stood at -2,300.97% in 2022, then spiked by 80,475bps to -1,496.23% in 2023, then soared by 33,092bps to -1,165.30% in 2024, then surged by 23,956bps to -907.37% in 2025.
  • Its EBITDA Margin stands at -907.37% for Q3 2025, versus -1,020.12% for Q2 2025 and -1,221.97% for Q1 2025.